The novel cardioprotective drug carvedilol was studied by both Raman spectroscopy and ab initio molecular orbital methods (using the density functional theory approach). The spectra, acquired both for the solid samples and DMSO solutions as a function of pH, were assigned in view of the calculated wavenumbers and intensities, and also based on the experimental data obtained for individual compounds which comprise the molecule, namely carbazole and 1,2-dimethoxybenzene. The pH dependence of the Raman pattern of carvedilol was studied, and the pK a value of its secondary amine group was determined (pK a = 8.25) through pH titration experiments. This kind of information is of great significance for the understanding of the biochemical role of carvedilol, which is strongly determined by the acid-base behaviour of the molecule.
INTRODUCTION

Carvedilol (f1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethylamino] propanol-(2)g
) is a compound displaying antioxidant properties, used in clinical practice for the treatment of cardiovascular diseases (hypertension, congestive heart failure or myocardial infarction). 1, 2 This drug was recently proposed to act through protection of the mitochondrial function, 3 -6 as cardiac dysfunctions are often correlated with changes in mitochondrial bioenergetics. Carvedilol behaves as a weak protonophore, carrying protons through the mitochondrial membrane, thus causing a lowering of the electric membrane potential () created by ejection of H C by the redox chain pumps. 7 In this way, carvedilol may be protonated in the cytoplasmic site, cross the membrane driven by the inner negative electric field and then release its amine proton into the matrix. This proposed cardioprotective effect is closely related to the acid-base characteristics of the molecule, which emphasizes the importance of a correct determination of its pK a value.
In a previous study, 7 a conformational analysis of carvedilol was carried out by ab initio self-consistent field molecular orbital (SCF-MO) calculations for the different protonation states of the molecule, and the corresponding proton affinities were obtained. In the present work, a spectroscopic vibrational study of the molecule was carried out and its pK a value was determined through analysis of the changes in the band intensities upon protonation.
EXPERIMENTAL
Ab initio MO calculations
The ab initio SCF-MO calculations (total geometry optimization as well as harmonic vibrational wavenumbers and intensities) were performed using the Gaussian 98W program, 8 with the split valence basis set 3-21G. 9 Molecular geometries were fully optimized by the Berny algorithm, using redundant internal coordinates:
10 the bond lengths to within ca 0.1 pm and the bond angles to within ca 0.1°. The final root-mean-square (r.m.s.) gradients were always less than 3 ð 10 4 hartree bohr 1 or hartree rad 1 .
Raman spectroscopy
The Raman spectra were recorded on a Jobin-Yvon T64000 triple monochromator Raman system (0.640 m, f /7.5) with holographic gratings of 1800 grooves mm 1 . The premonochromator stage was used in the subtractive mode. The detection system was a non-intensified CCD (chargecoupled device). Radiation of 514.5 nm line from an argon ion laser (Coherent Innova 300-05) was used for excitation, providing ca 80 mW at the sample position, and a 90°geom-etry was employed. The entrance slit was set to 200 µm and the slit between the premonochromator and the spectrograph was opened to 13.2 mm. An integration time of 5 s and 10-15 scans were used in all the experiments. Samples were sealed in Kimax glass capillary tubes of i.d. 0.8 mm. Under these conditions, the error in wavenumbers was estimated to be within 1 cm 1 . FT-Raman spectra were obtained for the carbazole sample with a Bruker RFS 100/S spectrophotometer. Radiation of 1064 nm line from an Nd:YAG laser was used for excitation, providing ca 100 mW at the sample position. The resolution was set at 2 cm 1 and a 180°geometry was employed. Spectra were obtained for both solid samples (at 15°C) and 0.5 mol dm 3 solutions (at 20°C). Band intensity ratios were evaluated by fitting Lorentzian bands to the experimental spectra.
Sample preparation
Dimethyl-sulfoxide (DMSO) was used as a solvent for carvedilol (0.5 mol dm 3 , owing to the low water solubility of this compound. The pH of the solutions was adjusted between 2.5 and 13.5 with HCl and CO 2 -free NaOH, using a Sargent-Welch pH-meter coupled to a Radiometer PHC3006-9 combined electrode.
Reagents
Carvedilol and carbazole (vetranal) were obtained from Boehringer and Fluka/Riedel-de Haën, respectively. DMSO (HPLC grade), 1,2-dimethoxybenzene (veratrole, 99%), HCl and NaOH (analytical grade) were purchased from Aldrich. 7 Protonation of the molecule was found to induce a severe change in the C carbazol OCC dihedral angle, from 79°(unprotonated compound) to 177°(protonated species) (Fig. 1) . In all cases, the molecule is stabilized through intramolecular (O)H ÐÐÐ O and/or (N)H ÐÐÐ O hydrogentype interactions, which are determinant of its acid-base characteristics and consequently of its biochemical effect in living cells. Tables comprising the optimized geometric parameters of carvedilol are available from the authors upon request. Figure 2 (A) displays the Raman spectrum of solid carvedilol, that was assigned based on its calculated harmonic Raman wavenumbers and intensities (Table 1) , as well as on the comparison with the experimental spectra obtained separately for two compounds which comprise the molecule, 1,2-dimethoxybenzene and carbazole [ Fig. 2 (B) and (C)]. Interestingly, these aromatic systems, situated at two opposite ends of the carvedilol molecule, hardly interact with each other, yielding rather localized vibrational modes, which may actually be considered as group wavenumbers. In fact, the spectrum obtained for carvedilol can be viewed as the result of a superposition of the individual spectra of carbazole and 1,2-dimethoxybenzene (Fig. 2) . A tentative assignment of the Raman patterns corresponding to these molecules is given in Table 1 . Good agreement is found between the present values and those recently reported for carbazole by Lao et al. 11 Figure 3 displays several Raman spectra of carvedilol solutions in DMSO. Apart from the features due to the solvent, the pattern observed is in close accord with the results obtained for the solid sample (Fig. 2) and thus with the assignments presented in Table 1 .
RESULTS AND DISCUSSION
The spectroscopic results obtained for these solutions, at distinct pH values, undergo clear changes in the region around 750 cm 1 (Fig. 3) , which reflect the presence of the protonated and unprotonated forms of a secondary amine group in the molecule (Fig. 1) . The corresponding protonation constant (pK a was therefore determined through Raman pH titration experiments. Through analysis of the spectra, it was verified that the protonation equilibrium can be monitored through the band at ca 747 cm 1 , assigned to the RNH 2 C group, as its intensity increases steadily on lowering the pH of the solution (Fig. 3) . This feature may then be used unequivocally as a measure of the concentration of the protonated form of the molecule. Upon obtaining spectra in a broad region of pH (from 2.5 to 13.5), the molar fractions of both the unprotonated and protonated species in solution were calculated from the Raman intensity of that band, and plotted as a function of pH (Fig. 4) . Finally, the pK a was determined as being 8.25, from the pH value at the crossing points of those curves. The band at ca 867 cm 1 , that remained unchanged, both in wavenumber and intensity, throughout the whole pH range studied, was used as an internal reference. Actually, the fact that this band, which was previously ascribed to a mixed mode due to the indole NH bending and ring deformation, 13, 14 is not affected by the variation in pH is good evidence that protonation occurs only in one of the nitrogen atoms of the carvedilol molecule (within its linear chain), the carbazole group remaining unchanged. In fact, the wavenumber of this Raman pattern is considered by some workers 14 as a probe of H-bonding occurring at the nitrogen atom of the indole group.
The pK a value now obtained in DMSO solution is in fairly good accord with that found in the literature for carvedilol in phosphate saline medium: pK a D 7.9.
15 Also, the results from the present study agree completely with those that we previously reported for the proton affinity of carvedilol. 7 In fact, having a weak affinity for protons (amine pK a D 8.25) and carrying a positive charge at physiological pH, this compound will be able easily to release H C within the mitochondrial matrix, acting as an efficient cationic protonophore, with relevance for a cardioprotection effect.
7
CONCLUSIONS
The Raman spectra of carvedilol were obtained and assigned for both the solid state and DMSO solution. Interpretation of the spectroscopic data was based on the calculated vibrational wavenumbers and intensities, obtained through ab initio SCF-MO methods, and on the experimental spectra for individual compounds which comprise the carvedilol molecule, namely 1,2-dimethoxybenzene and carbazole.
The present work clearly evidences the utility of Raman spectroscopy in the determination of pK a values in solution, provided that a clear pH dependence is detected in the spectroscopic pattern during the protonation process, and an unequivocal correlation between the bands undergoing variation and a particular degree of protonation of the molecule may be achieved. The pK a value of the secondary amine group of carvedilol, in DMSO solution, was now determined to be 8.25, in fairly good accord with that previously reported using analytical methods. 15 Moreover, the fact that the experimental and calculated Raman spectra found for carvedilol in the present work display very good agreement reflects a close similarity between the theoretical geometry and the real conformation of the molecule. This may be of significance in future studies aimed at the understanding of the structure-activity relationships associated with the biological role of this compound, already in clinical use.
